New Three-Drug combo aims to control Tough-to-Treat colon cancer
Disease control
Recruiting now
This study is testing a new oral drug, ABT-301, combined with two existing cancer immunotherapies (tislelizumab and bevacizumab) for people with a specific type of advanced colorectal cancer that has spread. The main goals are to find the safest dose of the new drug and see if th…
Phase: PHASE1, PHASE2 • Sponsor: Anbogen Therapeutics, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC